Skip to main content

Table 1 Description of pilot samples and study cohorts

From: Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis

 

Pilot samples

Cohort 1

Cohort 2

Cohort IF

Group

Case

Control

Case

Control

Case

Control

Case

Control

N individualsa

1

1

5

5

10

7

7

8

Sex ratio (F/M)

1:0

0:1

4:1

1:4

7:3

3:4

6:1

3:5

Age (mean ± SD)

42

92

45.4 ± 4.5

68.4 ± 21.6

60.3 ± 12.4

78.5 ± 7.9

63.6 ± 12.8

78.2 ± 5.1

PMI (mean ± SD)

11

13

17 ± 8.7

21 ± 7.4

17 ± 9.3

11 ± 11.4

15 ± 8.0

23 ± 3.7

N brain samples

4

1

7

5

10

7

7

8

Type lesion (N)

AL (1)

 

AL (2)

 

–

 

–

 

CAL (1)

–

–

–

 

CL (1)

CL (2)

CL (2)

–

 

NAWM (1)

NAWM (3)

NAWM (8)

NAWM (7)

 

Sample type

Bulk tissue and neurons

Neurons

Neurons

Meurons

Location

GM, WM, mixed

WM

WM

WM and GM

Modification

DNA methylation

DNA methylation

DNA methylation

Protein phosphorylation

Analysis

Bulk BS

(mixed 5mC/5hmC)

Bulk BS

(mixed 5mC/5hmC)

BS and oxBS

(5mC, 5hmC)

IF: P-CREB

  1. aThree individuals (2 MS cases and 1 control) overlapped between cohort 1 and 2, although different brain samples were used, and, eight individuals (5 MS cases and 3 controls) were used for both DNA methylation (cohort 2) and immunofluorescence (cohort IF) analyses, among which 4 brain specimens were identical. N number, F/M female/male, PMI post-mortem interval, AL active lesion, CL chronic lesion, CAL chronic active lesion, NAWM normal-appearing white matter, GM grey matter, WM white matter, BS bisulfite, oxBS oxidative bisulfite, 5mC methylation, 5hmC hydroxymethylation, P-CREB phosphorylated CREB, SD standard deviation, IF immunofluorescence